Get started

Pharmaceuticals

PFIZER Broke above its 2022 Bear Channel!Pfizer (PFE) broke and closed today above the Channel Down that has been dominating the 2022 Bear Market since the January 11 High. At the same time the 1D RSI has been ranging and while the 1D MA200 (orange trend-line) held successfully last time, we do expect one last test or for an even more comfortable long-term buy, the 1D MA50 (blue trend-line). As you may notice, the Fibonacci retracement levels since the All Time High, formed solid Resistance and Support levels during the downtrend, so after the next pull-back our target will by the 0.786 Fib at 57.35. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:PFE
by TradingShot
2
PXMD | Short Squeeze? | WatchingPaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
PLong
by DivergenceSeeker
5
Fading into PHARM negative trend.Pharming Group - 30d expiry- We look to Sell a break of 0.934 (stop at 0.993) Short term bias has turned negative. Daily signals are mildly bearish. A higher correction is expected. We are trading at overbought extremes. 0.936 has been pivotal. A break of 0.936 is needed to confirm follow through negative momentum. There is no clear indication that the downward move is coming to an end. Our profit targets will be 0.794 and 0.754 Resistance: 0.980 / 1.054 / 1.110 Support: 0.936 / 0.900 / 0.860 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:PHARMShort
by Saxo
SXTC | And Another One | LONGChina SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.
NASDAQ:SXTCLong
by DivergenceSeeker
2
EYPT | Short term bottom? | LONGEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
NASDAQ:EYPTLong
by DivergenceSeeker
LYEL | Pharma Stock Oversold | LONGLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
NASDAQ:LYELLong
by DivergenceSeeker
JOHNSON & JOHNSON Can reach $190 by FebruaryJohnson & Johnson (JNJ) has been trading within a long-term Bullish Megaphone pattern since the January 26 2021 High. The pattern has been having very structured Higher Highs and Higher Lows. At the moment the stock is on a bullish leg, after rebounding exactly on the 1D MA50 (blue trend-line) on November 11 and is also above the 1D MA200 (orange trend-line). The 1W MACD is on a Bullish Cross and the 1W RSI rebounded off a Lower Lows (Double) Bottom formation. The exact same sequence was last seem early this year on January. After one last pull-back, the stock then rallied to the top (Higher Highs trend-line) of the Bullish Megaphone. The Higher Highs seem to be following the 1.236 - 1.5 - 1.786 Fibonacci sequence and so do the Lows (0.236 - 0.5 - 0.786). The 1.786 Fib extension is a little over $190.00 and that is our current long target on JNJ. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
2
UNITED HEALTH Stronger than ever one last Resistance to go!The UnitedHealth Group (UNH) has been on a strong 3 day rise since the November 15 Low which was a Higher Low within a hyper long-term Bullish Megaphone pattern, with the trend-line holding since February 22 2021. On top of that it rebounded within the 1W MA50 (red trend-line) - 1D MA200 (orange trend-line) zone, which has more or less priced all prior major Higher Lows. The next barrier standing is the 553.00 - 559.00 Resistance Zone that is holding since the April 14 2022 High and has had another two rejections, forming an Ascending Triangle. Needless to say, a break above it would be a major bullish break-out signal. As to the target? That would be initially the 1.382 Fibonacci extension, around $590.00, which is the symmetrical of the Fibonacci retracement levels that have formed the last two Higher Lows. As seen on the chart, the November 15 2022 Low was made on the 0.5 Fib while the October 13 2022 on the 0.382 Fib. We can argue that if there is one more rejection on the Resistance Zone, then the 0.618 Fib is a candidate for the next Higher Low. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNHLong
by TradingShot
CTLT: Bottoming out?Catalent Short Term - We look to Buy at 63.84 (stop at 56.95) The primary trend remains bearish. Bespoke support is located at 63.30. Support could prove difficult to breakdown. We look for a temporary move lower. Preferred trade is to buy on dips. Our profit targets will be 82.27 and 88.00 Resistance: 82.50 / 100.00 / 120.00 Support: 63.30 / 48.00 / 30.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’ ). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:CTLTLong
by VantageMarkets
MODERNA has most likely bottomedModerna Inc (MRNA), a much discussed stock over the previous years, is having a +8% day, a very encouraging since following the rejection on the 1D MA50 (blue trend-line) three days ago. What's more interesting is that we have seen almost the same pattern in the stock's all time lows in 2019. As you see, the price since September has been on Lower Lows while the 1D RSI has been on Higher Lows, indicating a Bullish Divergence that is often seen on market bottoms before the price reverses. The very same Bullish Divergence was spotted from June 25 2019 until August 07 2019. It was also a remarkable 1D candle of +20% back then that signaled the sentiment shift. The price confirmed those bias when it broke above the 1D MA50. The break of the 1D MA200 (orange trend-line) a few days later opened the way for an incredible two year rise that was of course dominated by the COVID fundamentals mostly. It is worth noting that at the moment the 1D MA200 is too close to the 1D MA50 as opposed to 2019, so best to have our mark on the 1W MA100 (green trend-line) which has rejected both of 2022 uptrends in March 21 and August 04. It is exactly now where the 200.00 Resistance is (formed by the August 04 High). Also notice that the 1W MA200 (red trend-line) has made its appearance in October for the first time in history and provided the necessary Support for the early October push. ------------------------------------------------------------------------------- ** Please LIKE 👍, SUBSCRIBE ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support me, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- You may also TELL ME 🙋‍♀️🙋‍♂️ in the comments section which symbol you want me to analyze next and on which time-frame. The one with the most posts will be published tomorrow! 👏🎁 ------------------------------------------------------------------------------- 👇 👇 👇 👇 👇 👇 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NASDAQ:MRNALong
by TradingShot
ACHV | Time to Start Loading | LongAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
NASDAQ:ACHVLong
by DivergenceSeeker
BMY: Always bet on pharma!Bristol-Myers Squibb Co Short Term - We look to Buy a break of 72.34 (stop at 70.99) Price action has formed a bullish ascending triangle formation. This is positive for sentiment and the uptrend has potential to return. Neckline resistance 72.00. A break of the neckline is required to confirm the formation. Further upside is expected. Our profit targets will be 75.96 and 80.00 Resistance: 72.00 / 80.00 / 100.00 Support: 71.00 / 65.00 / 60.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:BMYLong
by VantageMarkets
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView
Roche Holding AG bullish scenario:The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The Triangle broke through the resistance line on 07/09/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 10 days towards 333.65 CHF. Your stop-loss order, according to experts, should be placed at 311.75 CHF if you decide to enter this position. Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:ROGLong
by legacyFXofficial
Aspen upcoming earningsJSE:APN mini rally following a positive trading statement quickly fizzled. Aspen JSE:APN reporters that EPS will be between 32% - 37%. Audited results are coming this week, the numbers are expected to remain the same. The share is trading below key levels, the stock will need great numbers to push the price up, a promising setup is the price trading above R160/share. Otherwise, the downtrend in the stock will continue, especially if the price drops to R136/share.
JSE:APN
by Trend_Trader_JSE
Cipla Buying Opportunity1) The US recession talks are rising day by day. The recession is to come, we just don't know when, but it will come. 2) Inflation is at an all-time high. The IT sector is tanking like anything. 3) The Pharma sector is known to be recession-proof and inflation-proof. People will never stop spending on medicine and healthcare, no matter how expensive it gets. 4) Cipla is consolidating at its previous swing high. 5) The pharma sector has already corrected 1/3 after the 2020 rally. 6) almost all the sectors have recovered except for IT and PHarma. I believe if pharma rallies, then CIPLA will be the one leading the rally.
NSE:CIPLALong
by aryanpachpute
Galapagos (GLPG.as) bearish scenario:The technical figure Triangle can be found in the Belgium company Galapagos NV (GLPG.as) at daily chart. Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. The Triangle has broken through the support line on 26/07/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 7 days towards 45.00 EUR. Your stop loss order according to experts should be placed at 56.70 EUR if you decide to enter this position. Galapagos agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities. Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio. Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:GLPGShort
by legacyFXofficial
GSK Death Cross my be hugely bullish after all !GlaxoSmithKlein (GSK) just formed a Death Cross on the 1D time-frame, which is when the 1D MA50 (blue trend-line) crosses below the 1D MA200 (orange trend-line). This is technically a bearish pattern but last time it formed (March 24 2020) was exactly on the bottom of the COVID crash and the price recovered rapidly. That was of course in the aftermath of the massive economic package in an attempt to support the economy from the lockdown but even now there is upside potential and some levels to consider on the short-term. As you see, since April 11, the stock has been trading within a perfect Channel Down. This indicates a systematic downtrend. As long as the 1D MA50 holds, such rises are sell opportunities towards a Lower Low, in which case its on the 0.236 now. Since we are trading so close to the 1D MA50, a tight sell now with the SL located at the top of the Channel Down, has an excellent Risk/ Reward ratio. Similarly, if the price breaks above the top of the Channel Down, the R/R is favorable in going on a tight buy targeting the upper Fibs and ultimately the 47.00 Resistance. Notice how the 1D RSI bounced off near the 30.00 oversold level, which has initiated massive rebounds another 4 times within the long-term Channel Up. -------------------------------------------------------------------------------------------------------- ** Please support this idea with your likes and comments, it is the best way to keep it relevant and support me. ** --------------------------------------------------------------------------------------------------------
NYSE:GSK
by TradingShot
1